The latest research and development progress and clinical trends of daprodustat

Daprodustat (Daprodustat) is an oral HIF-PH inhibitor. Its core mechanism is to simulate a hypoxic environment by inhibiting the hypoxia-inducible factor proline hydroxylase, causing the kidneys to produce more endogenous erythropoietin (EPO), thereby promoting erythropoiesis and increasing hemoglobin levels. Compared with traditional erythropoietin injections, daplestat can regulate hemoglobin more naturally, and its oral administration method significantly improves patient compliance and life convenience.

In recent years, the research and development and clinical application of daprexostat have continued to advance globally. A number of overseas multi-center randomized controlled studies have shown that daprostat can stably maintain hemoglobin levels in patients with chronic kidney disease before and during dialysis, while having less impact on blood pressure, iron metabolism and cardiovascular events. Studies have also shown that dapoxostat combined with iron therapy can further optimize hemoglobin control, reduce the need for blood transfusions, and reduce the risk of cardiovascular complications. Clinical observation shows that its efficacy can be maintained stably in patients with early-stage and late-stage chronic kidney disease, and it is well tolerated.

At the pharmacological level, daporostat regulates EPO expression through theHIF pathway and affects hepcidin levels, thereby improving iron utilization efficiency. This feature helps reduce the use of additional iron supplements and reduces cardiovascular risks caused by rapid elevation of hemoglobin. Overseas guidelines have gradually affirmed the status of HIF-PH inhibitors in the management of anemia in chronic kidney disease, especially for non-dialysis patients as the preferred oral regimen. They also emphasize the close monitoring of hemoglobin, blood pressure and iron metabolism indicators during medication, and adjust the dosage according to individual conditions.

Future research directions include long-term safety observation, comparison with otherHIF-PH inhibitors and traditional erythropoietin, and dose optimization strategies in patients with different comorbidities. Through these studies, doctors can develop more personalized treatment plans for patients and further improve hemoglobin maintenance stability and quality of life.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat